Antoine E. Soueid, MD, PharmD, JD1; Ibrahim Kassas, MD2; Jeffrey Rade, MD1; Nikolaos Kakouros, MBBS, MD(Res), PhD1
Antoine E. Soueid, MD, PharmD, JD1; ...
Newer antiplatelet therapy agents are reliable and have a fast onset of action, but have significantly higher cost, leading to compliance concerns. We adopted and evaluated an acute agent-switching strategy, using prasugrel or ticagrelor for...
Newer antiplatelet therapy agents are reliable and have a fast onset of action, but have significantly higher cost, leading to compliance concerns. We adopted and evaluated an acute agent-switching strategy, using prasugrel or ticagrelor for...
Newer antiplatelet therapy...